Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia

References

• Hehlmann R, Hochhaus A, Baccarani M; on behalf of the European LeukemiaNet. Chronic myeloid leukemia. Lancet 2007;370:342-50
   PubMed Web of Science ®Google Scholar
• Apperley JF, Part I. Mechanisms of resistance to imatinib in chronic myeloid leukemia. Lancet Oncol 2007;8:1018-29
   PubMed Web of Science ®Google Scholar
• Apperley JF, Part II. Management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007;8:1116-29
   PubMed Web of Science ®Google Scholar
• Ross DM, Branford S, Seymour JF, et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010;24(10):1719-24
   PubMed Web of Science ®Google Scholar
• Sobrinho-Simoes M, Wilczek V, Score J, et al. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood 2010;116(8):1329-35
   PubMed Web of Science ®Google Scholar
• Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular resistant disease. Blood 2011;118(13):3657-60
   PubMed Web of Science ®Google Scholar
• Chu S, McDonald T, Lin A, et al. Persistence of leukemia stem cells in chronic myelogeneous leukemia patients in prolonged remission with imatinib treatment. Blood 2011;118:5565-72
   PubMed Web of Science ®Google Scholar
• Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-20
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-51
   PubMed Web of Science ®Google Scholar
• Baccarani M, Deininger M, Rosti G, et al. EuroepanLeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 2013;122(6):872-84
   PubMed Web of Science ®Google Scholar
• O’Brien S, Abboud CN, Akhtari M, et al. Clinical Practice Guidelines in Oncology. Chronic myelogenous leukemia, Version 2.2014, National Comprehensive Cancer Network (NCCN). Available from: http://www.nccn.org
   Google Scholar
• Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of non-adherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009;113:5401-11
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic response on imatinib. J Clin Oncol 2010;28:2381-8
   PubMed Web of Science ®Google Scholar
• Dulucq S, Bouchet S, Turcq B, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008;112:2024-7
   PubMed Web of Science ®Google Scholar
• White DL, Dang P, Engler J, et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010;28:2761-7
   PubMed Web of Science ®Google Scholar
• Angelini S, Soverini S, Ravegnini G, et al. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica 2013;98(2):193-200
   PubMed Web of Science ®Google Scholar
• Thomas J, Wang L, Clark RE, et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739-45
   PubMed Web of Science ®Google Scholar
• Ng KP, Hillmer AM, Chuah CTH, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 2012;18(4):521-8
   PubMed Web of Science ®Google Scholar
• Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003;101:2368-73
   PubMed Web of Science ®Google Scholar
• Soverini S, Gnani A, Colarossi S, et al. Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009;114:2168-71
   PubMed Web of Science ®Google Scholar
• Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutations analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011;118(5):1208-15
   PubMed Web of Science ®Google Scholar
• Gruber FX, Ernst T, Porkka K, et al. Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant patients. Leukemia 2012;26:172-7
   PubMed Web of Science ®Google Scholar
• Khorashad JS, Kelley TW, Szankasi P, et al. BCR-ABL1 compound mutations in tyrosine kinase inhibitor resistant CML: frequency and clonal relationship. Blood 2013;121:489-98
   PubMed Web of Science ®Google Scholar
• Soverini S, De Benedittis C, Machova Polakova K, et al. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood 2013;122(9):1634-48
   PubMed Web of Science ®Google Scholar
• Jabbour E, Jones D, Kantarjian HM, et al. Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in-vitro sensitivity of BCR-ABL kinase domain mutations. Blood 2009;114:2037-43
   PubMed Web of Science ®Google Scholar
• Fabarius A, Leitner A, Hochhaus A, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011;118:6760-8
   PubMed Web of Science ®Google Scholar
• Luatti S, Castagnetti F, Marzocchi G, et al. Additional chromosome abnormalities in Philadelphia-positive clone: adverse prognostic influene on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood 2012;120(4):761-7
   PubMed Web of Science ®Google Scholar
• Verma D, Kantarjian H, Shan J, et al. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer 2010;116:2673-81
   PubMed Web of Science ®Google Scholar
• Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 2011;25:7-22
   PubMed Web of Science ®Google Scholar
• Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37
   PubMed Web of Science ®Google Scholar
• Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008;112(8):3330-8
   PubMed Web of Science ®Google Scholar
• Müller MC, Cross NC, Erben P, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009;23(11):1957-63
   PubMed Web of Science ®Google Scholar
• Cross NCP, White HE, Müller MC, et al. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012;26(10):2172-5
   PubMed Web of Science ®Google Scholar
• Deininger M, O’Brien S, Guilhot F, et al. International randomized study of interferon and STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib [abstract]. Abstract 1126. Presented at: 51st ASH Annual Meeting, 5-8 December 2009; New Orleans, LA, USA
   Google Scholar
• De Lavallade H, Apperley JF, Khorashad J, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analsys. J Clin Oncol 2008;26:3358-63
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian HM, Goldberg SL, et al. High-dose imatinib in newly diagnosed chronic phase chronic myeloid leukemia: high rated of rapid cytogenetic and molecular responses. J Clin Oncol 2009;27:4754-9
   PubMed Web of Science ®Google Scholar
• Cervantes F, Lopez-Garrido P, Montero MI, et al. Early intervention during imatinib therapy on patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica 2010;95(8):1317-24
   PubMed Web of Science ®Google Scholar
• Faber E, Muzik J, Koza V, et al. Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 200 – a report from the population-based CAMELIA registry. Eur J Haematol 2011;87:157-68
   PubMed Web of Science ®Google Scholar
• Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus Peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010;363:2511-21
   PubMed Web of Science ®Google Scholar
• Gugliotta G, Castagnetti F, Palandri F, et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML working party. Blood 2011;117(21):5591-9
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011;29:1634-42
   PubMed Web of Science ®Google Scholar
• Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010;116(19):3758-65
   PubMed Web of Science ®Google Scholar
• Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012;30(3):232-8
   PubMed Web of Science ®Google Scholar
• Branford S, Kim DW, Soverini S, et al. Initial molecular response at 3 months may predict both responses and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia. J Clin Oncol 2012;30(35):4323-9
   PubMed Web of Science ®Google Scholar
• Hanfstein B, Muller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive of long-term progression-free and overall survival in chronic myeloid leukemia. Leukemia 2012;26:2096-102
   PubMed Web of Science ®Google Scholar
• Marin D, Hedgley C, Clark RE, et al. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood 2012;120(2):291-4
   PubMed Web of Science ®Google Scholar
• Brummendorf TH, Kantarjian HM, Gambacorti-Passerini C, et al. Assessment of early molecular response as a predictor of long-term clinical outcomes in the phase 3 BELA study. Abstract 69. Presented at: 54th Congresso ASH, 8-11 December 2012, Atlanta, GA, USA
   Google Scholar
• Jain P, Kantarjian HM, Nazha A, et al. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood 2013;121(24):4867-74
   PubMed Web of Science ®Google Scholar
• Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predict outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 2014;123(9):1353-60
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial. Blood 2014;123:494-500
   PubMed Web of Science ®Google Scholar
• Neelakantan P, Gerrard G, Lucas C, et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early interventions strategies. Blood 2013;121:2739-42
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic. myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012;119(5):1123-9
   PubMed Web of Science ®Google Scholar
• Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012;26(10):2197-203
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles FJ, Bhalla KN, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood 2011;117(4):1141-5
   PubMed Web of Science ®Google Scholar
• Giles FJ, le Coutre PD, Pinilla-Ibartz J, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013;27:107-12
   PubMed Web of Science ®Google Scholar
• Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010;95:232-40
   PubMed Web of Science ®Google Scholar
• Rea D, Vellenga E, Junghanss C, et al. Six-year follow-up of patients with imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia receiving dasatinib. Abstract 1430. Presented at: 17th Congresso EHA, 14-17 Giugno 2012; Amsterdam, Netherland
   Google Scholar
• Cortes JE, Kantarjian HM, Brummendorf TK, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia-chromosome positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011;118:4567-76
   PubMed Web of Science ®Google Scholar
• Khoury HJ, Cortes JE, Kantarjian HM, et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012;119(15):3403-12
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory chromosome-positive leukemias. N Engl J Med 2012;367:2075-88
   PubMed Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosom-positive leukemias. N Engl J Med 2013;369(19):1783-96
   PubMed Web of Science ®Google Scholar
• Milojkovic D, Apperley JF, Gerrard G, et al. Response to second line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. Blood 2012;119(8):1838-43
   PubMed Web of Science ®Google Scholar
• Tam CS, Kantarjian H, Garcia-Manero G, et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 2008;112:516-18
   PubMed Web of Science ®Google Scholar
• Fava C, Kantarjian HM, Jabbour E, et al. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine linase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blastic phase. Blood 2009;113:5058-63
   PubMed Web of Science ®Google Scholar
• Milojkovic D, Nicholson E, Apperley JF, et al. Early prediction of success or failure of treatment with second generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 2010;95:224-31
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, O’Brien S, et al. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood 2011;117(6):1822-7
   PubMed Web of Science ®Google Scholar
• Jabbour E, le Coutre PD, Cortes J, et al. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. Leukemia 2013;27(4):907-13
   PubMed Web of Science ®Google Scholar
• Picard S, Titier K, Etienne G, et al. Through imatinib plasma levels are associated with both cytogenetic and molecular responses to standard dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496-9
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian HM, Jones D, et al. Imatinib mesylate dose escalation is associated with durable response in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009;113:2154-60
   PubMed Web of Science ®Google Scholar
• O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16:401-12
   PubMed Web of Science ®Google Scholar
• Bjorkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011;29:2514-20
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O’Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 2012;119(9):1981-7
   PubMed Web of Science ®Google Scholar
• Baccarani M, Pane F, Saglio G. Monitoring treatment of chronic myeloid leukemia. Haematologica 2008;92:161-9
   Google Scholar
• Jabbour E, Deininger M, Hochhaus A. Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2011;25:201-10
   PubMed Web of Science ®Google Scholar
• Rosti G, Castagnetti F, Gugliotta G, et al. Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML. Cancer Treat Rev 2012;38:241-8
   PubMed Web of Science ®Google Scholar
• Steegmann JL, Cervantes F, le Coutre P, et al. Off-target effects of BCR-ABL1 inhibitors and their potential long term implications in patients with chronic myeloid leukemia. Leuk Lymphoma 2012;53(12):2351-62
   PubMed Web of Science ®Google Scholar
• Futosi K, Nemeth T, Pick R, et al. Dasatinib inhibits proinflammatory functions of mature human neutrophils. Blood 2012;119(21):4981-91
   PubMed Web of Science ®Google Scholar
• Zarbock A. The shady side of dasatinib. Blood 2012;119(21):4817-18
   PubMed Web of Science ®Google Scholar
• Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia 2013;27(6):1310-15
   PubMed Web of Science ®Google Scholar
• Kim TD, Rea D, Schwarz M, et al. Peripheral artery occlusive disease (PAOD) in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia 2013;27(6):1316-21
   PubMed Web of Science ®Google Scholar
• Efficace F, Baccarani M, Breccia M, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared to the general population. Blood 2011;118(17):4554-60
   PubMed Web of Science ®Google Scholar
• Efficace F, Baccarani M, Breccia M, et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia 2013;27(7):1511-19
   PubMed Web of Science ®Google Scholar
• Williams LA, Garcia Gonzales AC, Ault P, et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood 2013;122(5):641-7
   PubMed Web of Science ®Google Scholar
• Efficace F, Baccarani M, Breccia M, et al. International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res 2013. [Epub ahead of print]
   Google Scholar
• Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010;11:1029-35
   PubMed Web of Science ®Google Scholar
• Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013;122:515-22
   PubMed Web of Science ®Google Scholar
• Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014;32:424-30
   PubMed Web of Science ®Google Scholar